Picture of Xeris Biopharma Holdings logo

XERS Xeris Biopharma Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

REG - JP Morgan Sec LLC Xeris Pharmaceutical - Xeris Pharmaceuticals, Inc 8.3




 



RNS Number : 1993I
J.P. Morgan Securities LLC
10 August 2021
 

Ap19

 

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC

Company dealt in

Xeris Pharmaceuticals, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

$0.001 common stock

Date of dealing

09 August 2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

3,553,222                5.34

134,114             0.20

(2) Derivatives (other than options)

124,443                0.19

 

(3) Options and agreements to purchase/sell

 

 

Total

3,677,665             5.53

134,114             0.20

             

 

 

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD)

 

(Note 5)

Purchases

 

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

Sales

352

 

 1,500

 500

 8,300

 3,950

 13,719

 10,400

 53,564

 11,100

 657

 700

 15,769

 35,730

 9,527

 3,611

 10,065

 10,900

 13,200

 4,500

 23,112

 2,000

 1,095

 6,990

 30,725

 16,911

 9,918

 8,482

 5,443

 17,803

 2,100

 10,296

 2,933

 600

 12,582

 4,000

 4,279

 8,642

 2,403

 24,818

 2,500

 9,281

 1,700

 1,235

 4,102

 4,781

 10,510

 7,607

 19,378

 2,854

 13,600

2.4100          USD

                       

2.3250          USD

2.3350          USD

2.3550          USD

2.3557          USD

2.3650          USD

2.4000          USD

2.4023          USD

2.4050          USD

2.4054          USD

2.4057          USD

2.4069          USD

2.4079          USD

2.4090          USD

2.4092          USD

2.4100          USD

2.4113          USD

2.4129          USD

2.4149          USD

2.4150          USD

2.4190          USD

2.4200          USD

2.4220          USD

2.4242          USD

2.4250          USD

2.4263          USD

2.4285          USD

2.4300          USD

2.4308          USD

2.4321          USD

2.4327          USD

2.4332          USD

2.4333          USD

2.4350          USD

2.4353          USD

2.4370          USD

2.4375          USD

2.4400          USD

2.4450          USD

2.4452          USD

2.4455          USD

2.4468          USD

2.4500          USD

2.4545          USD

2.4547          USD

2.4550          USD

2.4553          USD

2.4567          USD

2.4600          USD

2.4650          USD

 

 

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(USD) (Note 5)

 

 

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

                         

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other 

person relating to the voting rights of any relevant securities under any option referred to on this form or relating 

to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred 

to on this form is referenced. If none, this should be stated.

 

     None

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Date of disclosure

 10 August 2021

Contact name

Alwyn Basch

Telephone number

0207 742 7407

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEDZGMRFGDGMZM

Recent news on Xeris Biopharma Holdings

See all news